Imlunestrant/Abemaciclib/Selinexor in Ovarian and Endometrial
Imlunestrant/Abemaciclib/Selinexor in Ovarian and Endometrial
Not yet recruiting · NCT07832227 · Registry updated 2026-09-21Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Imlunestrant/Abemaciclib/Selinexor in Ovarian and Endometrial | Adnexal Diseases, Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, Genital Diseases, Neoplasms by Site, Urogenital Diseases, Urogenital Neoplasms, endocrine system disorder, endometrium neoplasm, female reproductive system disorder, female reproductive system neoplasm, gonadal disorder, low-grade serous ovarian carcinoma, malignant endocrine neoplasm, neoplasm, ovarian cancer, ovarian disorder, uterine disorder | Not yet recruiting | Phase 2 | 2026-09-21 | NCT07832227 |
3 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| Dana-Farber Cancer Institute | 324 |
| Eli Lilly and Company | 370 |
| Karyopharm Therapeutics Inc | 25 |
0 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| No products are listed yet. | |||